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E-caderin expression in renal cell cancer and its significance in
metastasis and survival
A Katagiri, R Watanabe and Y Tomita
Department of Urology, Niigata University School ofMedicine, Asahimachi I Niigata951 Japan.
Sumary Decreased expression of E-cadherin (E-CD). a homotypic intercellular adhesion molecule, is
considered to elicit detachment of tumour cells from primary lesions, which is the first stage of metastasis.
Since renal cell cancer (RCC) shows a relatively high frequency of metastasis, we focused our interest on E-CD
expression in RCC and its clinicopathological implications. We examined E-CD expression in normnal kidney
and RCC by immunohistochemical staining. In normal kidney, E-CD expression was localised in distal tubules
and collecting ducts. In RCC, 20 of 106 primary lesions (18.9%) expressed E-CD. whereas none showed
positive staining for eight metastatic lesions. There was a statistically significant correlation between loss of
E-CD expression and advanced stages of RCC. Kaplan-Meier analysis showed better prognosis in the group
with preserved E-CD expression than without E-CD expression (Cox-Mantel test. P = 0.022, the average
follow-up was 32 months or until death). This study suggests that the patients with decreased E-CD expression
may be associated with metastasis, resulting in poor prognosis. However, frequency of E-CD expression in
RCC is lower than in other cancers, which may be derived from the localised distribution of E-CD expression
in normal kidney.
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It is well known that cadherins, a family of Ca2+-dependent
intercellular adhesion molecules, play essential roles in
organogenesis and in the maintenance of normal structure
and function (Behrens et al., 1985; Eidelman et al., 1989;
Takeichi, 1991). Recently, E-cadherin (E-CD), a subclass of
cadherins, has come to be considered to be important as an
inhibitory factor in metastasis (Behrens et al., 1985; Frixen et
al., 1991; Takeichi, 1991). The first stage of metastasis is
detachment of tumour cells from the primary lesion, which is
induced by an alteration of intercellular adhesion. Behrens et
al. (1985) demonstrated that Madin-Darby canine kidney
epithelial cells have invasive properties when intercellular
adhesion is inhibited by anti-E-CD antibodies. In a report on
various human cell lines, Frixen et al. (1991) showed that loss
of E-CD can generate an invasive phenotype, which can be
prevented by transfection with E-CD cDNA. Clinically, the
correlation between decreased E-CD expression and advanc-
ed stages or dedifferentiation was also reported in a variety
of tumours (Frixen et al., 1991; Shiozaki et al., 1991; Oka et
al., 1992; Umbas et al., 1992; Bringuier et al., 1993; Oka et
al., 1993; Terpe et al., 1993). However, reports in relation to
the prognosis ofmalignant tumours have been rare until now
(Bringuier et al., 1993).
The clinical course of renal cell cancer (RCC) is charac-
tenised by the appearance of metastases even after a long
period with no evidence of disease. This results from mic-
rometastases that are not recognised at the time of nephrec-
tomy. However, at present, there are no effective methods to
predict the occurrence of metastasis. E-CD expression in
RCC has been rarely reported (Eidelman et al., 1989; Terpe
et al., 1993), and has not been reported at all in relation to
prognosis. Therefore, to clarify the significance of E-CD in
metastasis and prognosis of RCC, we detected E-CD expres-
sion in RCC by immunohistochemical staining and inves-
tigated the relationship between E-CD expression and
clinicopathological features including prognosis. In addition,
we also examined E-CD expression in metastatic lesions to
confirm the correlation between loss of E-CD expression and
metastasis.
Materals and methods
Patients andspecimens
A total of 106 patients with RCC who underwent radical
nephrectomy at the Urological Department of Niigata
University Hospital or related hospitals were included in this
study. The average patient age at the time of operation was
57.9 years, ranging from 34 to 84 years. Eight metastatic
lesions (four brain, one bone, one lung, one lymph node and
one subcutaneous skin tissue) were also examined. Nine spec-
imens of normal renal tissues were obtained from an un-
affected portion of the removed kidney. None of the patients
investigated in this study was treated before surgery. Sur-
gically obtained specimens were snap frozen in isopentane
precooled in dry ice-acetone. Serial cryostat sections at
5 mm were stored at - 20°C until use. Histological examina-
tion was performed on haematoxylin and eosin (H&E)-stain-
ed sections. Pathological staging was determined according to
the TNM classification of malignant tumours (UICC, 1989).
The 106 specimens included nine stage 1, 58 stage 2, 21 stage
3 and 18 stage 4; 53 grade 1, 41 grade 2 and 4 grade 3.
Immunohistochemical staining
Anti-E-CD monoclonal antibody (HECD-1, Takara
Biomedicals, Tokyo, Japan) was used in this study, and
immunoperoxidase staining was performed by modifying the
streptavidin-biotin bridge technique described previously
(Katagiri et al., 1993). Briefly, serial sections were air dnred
for 30 min and fixed in cold 4% paraformaldehyde with
1 mMlV' Ca2" for 30min. After rehydration with 0.01 M
pH 7.2 Tris-buffered saline containing 1 mM Ca2" (TBS+),
the sections were incubated in TBS+ containing 20% normal
sheep serum (Antibodies, Davis, CA, USA) for 30 min.
Endogenous biotin was blocked using an Endogenous Biotin
Blocking Kit (Vector Laboratories, Burlingame, CA, USA).
The sections were then incubated with primary antibody
diluted 1:500 overnight followed by incubation with bio-
tinylated anti-mouse immunoglobulin (Amersham Interna-
tional, Amersham, Bucks, UK) diluted 1:50 in TBS+ con-
taining 20% human type AB serum (Biological Speciality,
Landscale, PA, USA) for 15 min. Subsequently, they were
incubated with streptavidin peroxidase (Amersham) diluted
1:50 in TBS+ for 15 min. Each step was followed by washing
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1994in TBS+ with three changes of the buffer. The sections were
immersed in 0.05% diaminobenzidine (Sigma, St Louis, MO,
USA) and 0.01% hydrogen peroxide in 0.05 mol 1-1 Tris HCI
buffer for 3-5 min to visualise the reaction products. After
washing in tap water, the specimens were counterstained with
Mayer's haematoxylin and mounted with Eukitt (O. Kulder,
Freiburg, Germany) after dehydration in a graded ethanol
series and xylene. We evaluated E-CD expression in RCCs
using normal renal tissues as a positive control. As a negative
control, the monoclonal antibody, HECD-1, was replaed by
anti-Leul2 (Becton Dickinson, Mountain View, CA, USA), a
mouse monoclonal antibody of the same subclass (IgGI).
Evaluation ofthe staining
When reacted with HECD-1, most of tumours showed mem-
branous staining except for one case which showed cytoplas-
mic staining with membranous expression and was evaluated
as positive. In this study, almost all of reacted specimens
showed diffuse staining pattern in tumours. Although a range
of staining intensity was observed in this study, specimens
with diffuse and definite staining as compared with the
negative control were designated as positive.
Results
E-CD expression in normal kidney and RCC
Normal distal tubules and collecting ducts showed a uniform
expression of E-CD mainly on their cell surfaces, whereas
E-CD expression on proximal tubules was scattered and
doubtful (Figure 1). In RCC, 20 of 106 primary lesions
(18.9%) showed E-CD expression (Table I and Figure 1).
None of eight metastatic lesions in brain, bone, lung, lymph
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node and subcutaneous skin tissue expressed E-CD. In cases
where specimens of primary and metastatic lesions were
obtained, E-CD expression was lost at both sites (Table II
and Figure 1).
Correlation between E-CD expression and clinicopathological
features
Absence of E-CD expression was correlated with the
advanced stages (stage 3 or 4, P<0.01 in chi-square test,
Table I). All grade 3 tumours and most grade 2 tumours lost
E-CD expression (not significant in chi-square test, Table I).
There was no difference in adjuvant therapy among the
groups.
Correlation between E-CD expression andprognosis
Kaplan-Meier actual statistics were used to evaluate the
relationship between E-CD expression and disease outcome.
Figure 2 is the Kaplan-Meier curve comparing survival of
patients based on E-CD expression, and demonstrates a
statistically significnt difference between the group with E-
CD expression and the group without E-CD expression (P =
0.022 in Cox-Mantel test). An apparent difference in disease-
free survival fell short of statistical significance (P = 0.078 in
Cox-Mantel test, Figure 3). Only 1 of 20 patients with
preserved E-CD expression had metastasis within 14 months,
dying within 44 months after nephrectomy.
In this study, we examined the expression of E-CD in normal
kidney and RCC. In previous studies by Eidelman et al.
Fugwe 1 E-CD expression in normal kiey and RCC. In normal kidny (a) E-CD was detected mainly on the cell membrane of
distal tubuks and collecing ducts. A primary lesion of RCC (b) showed peerved E-CD expion (clear cell cancer, grade 1,
stage 2). Metastatic lesions of RCC in boe (right side of c) and skin (right side of 4) lacked E-CD expreion, whereas the
epidermis showed distinct positive staining (left side of i). Scale bars = 75pm.E.cabwrin hil red canw
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Table I Relationship between E-CD expression and clinicopatho-
logical characteristics
E-CD(+) E-CD(-}
No. (O) 20 (18.9} 86 (81.1)
Mean age (range) 58.3 (34-84) 57.8 (34- 78
Stage
1 1 8
2 18 40
3 1 20
4 0 18
Grade
1 14 39
2 5 36
3 0 4
Unknown 1 7
INF
16 43
2 23
0 3
Unknown 2 17
aLoss of E-CD expression was correlated with advanced stages (P<
0.01 in chi-square test). bHistological typing of proliferation or
invasiveness: INF, m, expansive pattern; INF P, intermediate pattern;
INF , infiltrating pattern (Japanese Urological Association et al.,
1992).
Table I E-CD expression in primary and metastatic lesions
Case Primary
no. Cell type' Grade' INP lesion Metastatic lesion
81 c>g 3 Brain
104 c>g 1 Brain
120 b b b Brain
116 c 2 m Brain
112 b b b c Bone
76 c 1 X Lung
86 c 2 c Lymph node
Skin
c, clear cell; g, granular cell; INF, the same abbreviations as Table I.
'Pathological findings ofprimary lesion.bUnjknown.CThespecuien was
not obtained because the nephrectomy for case 112 was performed
before we started to stock specimens.
(1989) and Shimoyama et al. (1989). E-CD was detected
inimunohistochemically in almost all epithelial tissues. They
reported that E-CD expression was mainly observed in distal
tubules and collecting ducts in normal kidney, which is con-
sistent with the results of this study. In malignant tumours.
the frequency of E-CD expression has been reported as fol-
lows: 96% (29/30) in oesophageal cancer, 78% (84/106) in
gastric cancer, 89% (107/120) in breast cancer, 84% (71/84)
in prostate cancer and 92% (45/49) in bladder cancer (all
data included reduced expressions - Shiozaki et al., 1991;
Oka et al., 1992, 1993; Umbas et al., 1992; Bringuier et al.,
1993). With RCC, Terpe et al. (1993) reported that E-CD
expression was observed in 9 (29%) of 31 specimens. In this
study, we examined E-CD expression in a larger number of
RCCs and found that around 20% of RCCs expressed E-CD
immunohistochemically. Although RCC can be generated
from all types of renal tubule or collecting duct (Kikuchi et
al., 1987), over two-thirds of RCCs are considered to
originate from proximal tubules, which do not show a
definite E-CD expression immunohistochemically. This may
be the reason for the lower frequency of E-CD expression in
RCC compared with other cancers. Concerning the expres-
sion of cadherins in other types, it has been reported that a
member of N-cadherin family, A-CAM, shows expression in
the proximal tubule of human adult kidney (Nouwen et al.,
1993).
Recently, the significance of E-CD expression in acquisi-
tion of invasive properties has been reported in relation to
the transformation of malignancy. In previous studies of
various human cell lines, it was found that the loss of E-CD
or inhibition of E-CD function by anti-E-CD monoclonal
antibody could generate the invasive phenotype (Behrens et
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al.. 1985: Frixen et al.. 1991). In clinical specimens, correla-
tion between E-CD expression and differentiation has been
reported in human cancers of bladder. breast, head and neck.
lung. pancreas. prostate, stomach and also in RCC (Frixen et
al.. 1991; Shiozaki et al.. 1991; Umbas et al.. 1992; Oka et
al.. 1992. 1993; Bringuier et al.. 1993; Terpe et al., 1993). In
this study, E-CD expression seemed likely to be lost in
tumours with a higher grade. invasive growth pattern and of
an advanced stage. In addition, preserved E-CD expression
was associated with better survival than reduced E-CD ex-
pression. These results are compatible with the idea that the
detachment of tumour cells as a result of decreased E-CD
expression elicits the invasive phenotype and leads to metas-
tasis.
In this study, none of the metastatic lesions showed E-CD
expression. which supports the correlation between the loss
of E-CD and metastasis in RCC. In an immunohistochemical
study of gastric cancer, Oka et al. (1992) demonstrated that
E-CD expression in distant metastatic lesions was not neces-
sarily reduced in some target organs. They speculated that
E-CD expression at the site where tumour cells come into
contact might contribute to metastasis, and that instability of
E-CD expression or impaired function might induce metas-
tasis. According to the immunohistochemical studies by
Eidelman et al. (1989) and Shimoyama et al. (1989), the
metastatic sites evaluated in this study, i.e. bone, brain, lung
and skin, did not show E-CD expression except for the
epidermis and alveolar lining of the lung. From our results,
therefore, it is unclear whether RCC cells with positive E-CD
could metastasise to an organ composed of E-CD-positive
normal cells. Umbas et al. (1992) also reported on hetero-
geneous E-CD expression in metastatic lesions of prostate
cancer and suggested temporal down-regulation of E-CD
expression or other factors that could overcome the E-CD
function.E-cadherin inreWlcalcancer
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In recent years. it has become apparent that cadhenn
functions as a complex called adherens junction that includes
several other proteins such as catenins and links to actin
filaments (Takeichi, 1991). Hirano et al. (1992) demonstrated
that transfection of x-catenin cDNA to cells which do not
show the homotypic adhesion, in spite of preserved E-CD
expression. can bring about aggregation and the arrangement
of the cells. It has also been found that tyrosine phosphoryla-
tion of cadherin and catenins inhibits the cadherin-associated
functions (Behrens et al.. 1993). which suggests the possibility
of transient modification of the intercellular adhesion.
In conclusion, we demonstrated the clinical value of E-CD
expression in RCC as a good prognostic factor. Examination
of E-CD in RCC might be beneficial to the evaluation of the
metastatic potential of RCC cells resulting in the patient's
prognosis. However, as mentioned above. other important
molecules or factors which play with E-CD in cell to cell
adhesion. including A-CAM, catenins and tyrosine phos-
phorylation of adherens junction, should be taken into
account.
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